CD28 co-stimulation: novel insights and applications in cancer immunotherapy

Lotze, Michael T.; Olejniczak, Scott H.; Skokos, Dimitris

doi:10.1038/s41577-024-01061-1

Nat Rev Immunol

2024

DOI: 10.1038/s41577-024-01061-1

|View full text |Cite

CD28 co-stimulation: novel insights and applications in cancer immunotherapy

Michael T. Lotze,

Scott H. Olejniczak,

Dimitris Skokos

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 220 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Kidney cancer: From tumor biology to innovative therapeutics

Rinaldi,

Senatore,

Feliciello

et al. 2025

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Kidney cancer: From tumor biology to innovative therapeutics

Rinaldi,

Senatore,

Feliciello

et al. 2025

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes

Franzese

2024

IJMS

View full text Add to dashboard Cite

This review explores some of the complex mechanisms underlying antitumor T-cell response, with a specific focus on the balance and cross-talk between selected co-stimulatory and inhibitory pathways. The tumor microenvironment (TME) fosters both T-cell activation and exhaustion, a dual role influenced by the local presence of inhibitory immune checkpoints (ICs), which are exploited by cancer cells to evade immune surveillance. Recent advancements in IC blockade (ICB) therapies have transformed cancer treatment. However, only a fraction of patients respond favorably, highlighting the need for predictive biomarkers and combination therapies to overcome ICB resistance. A crucial aspect is represented by the complexity of the TME, which encompasses diverse cell types that either enhance or suppress immune responses. This review underscores the importance of identifying the most critical cross-talk between inhibitory and co-stimulatory molecules for developing approaches tailored to patient-specific molecular and immune profiles to maximize the therapeutic efficacy of IC inhibitors and enhance clinical outcomes.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

CD28 co-stimulation: novel insights and applications in cancer immunotherapy

Cited by 2 publications

References 220 publications

Kidney cancer: From tumor biology to innovative therapeutics

Kidney cancer: From tumor biology to innovative therapeutics

Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes

Contact Info

Product

Resources

About